

Date: 01.09.2023

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001.

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 01.09.2023

Ref: Regulation 30 and 33 along with Schedule III of SEBI(LODR) Regulations, 2015

With reference to the subject cited, this is to inform the exchanges that at the Board Meeting of Sangam Healthcare Products Limited held on Friday, 01.09.2023 at 04.00 P.M at the registered office of the company, approved the following items of business:

1. Audited Financial results together with Statement of Assets and Liabilities and Statement of Cash flow for the quarter and year ended 31.03.2023 (enclosed).
2. Limited review report for the Quarter and year ended 31-03-2023 (enclosed).

The meeting concluded at 5:00 P.M.

This is for your information and records.

Thanking You,

For and on Behalf of the
Sangam Healthcare Products Limited

A. Bala Gopal
A. Bala Gopal
Managing Director
(DIN: 01702903)



To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001

Date: 01.09.2023

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.


Ref: Sangam Health Care Products Ltd (BSE Scrip Code: 531625)

I, Ashok Kumar Jain, Managing Director of M/s. Sangam Health Care Products Limited hereby declare that, the Statutory Auditors of the company, M/s. M.M.Reddy & Co., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Standalone & Consolidated financial results of the company for year ended 31st March, 2023.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide Circular No. CIR/CFD/CMD/ 56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,
For Sangam Health Care Products Limited



D. Bhagat Reddy
Managing Director

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MAR 31, 2023

Sl No.	Particular	Quarter ended			Year ended	
		31.03.2023 [Audited]	31.12.2022 [Un-audited]	31.03.2022 [Audited]	31.03.2023 [Audited]	31.03.2022 [Audited]
1	Revenue from Operations	225.90	295.12	358.86	1,075.99	870.43
2	Other Income	-	-	-	-	-
	Total Income	225.90	295.12	358.86	1,075.99	870.43
3	Expenses:					
	Material consumed	145.47	149.47	177.15	494.61	592.86
	Changes in inventories	-	-	-21.19	-	-61.34
	Employees benefit expenses	46.41	83.84	80.59	303.10	201.55
	Finance Cost	3.03	-	0.84	3.01	-
	Depreciation & amortization expenses	30.43	30.43	39.04	121.72	121.72
	Other expenses	54.42	57.36	43.83	299.04	188.17
	Total Expenses	279.74	321.10	320.26	1,212.48	1,043.06
4	Profit before exceptional and extraordinary items and tax (3 -	-53.85	-25.98	38.59	-136.49	-172.63
5	Exceptional items	-	-	-	-	-
6	Profit before tax	-53.85	-25.98	38.59	-136.49	-172.63
7	Tax expense:					
	(1) Current tax	-	-	-	-	-
	(2) Deferred tax	-	-	-	20.10	37.31
8	Net Profit After Tax	-53.85	-25.98	38.59	-116.39	-209.94
9	Other Comprehensive Income					
A	Items that will not be reclassified to statement of Profit & loss:					
	(i) remeasurement benefits for the define benefit plans	-	-	-	-	-
	(ii) equity instruments through other comprehensive income	-	-	-	-	-
	(iii) Deferred tax relating to the above items	-	-	-	-	-
B	Net fair value loss on instrument in equity instruments	-53.85	-25.98	38.59	-116.39	-209.94
	Total Other Comprehensive Income / loss	-	-	-	-	-
10	Total Other Comprehensive Income	-	-	-	-	-
11	Paid-up Equity share capital	1,486.00	1,486.07	1,486.07	1,486.07	1,486.07
12	Other Equity	-	-	-	-	-
13	Earnings per equity share:					
	(i) Basic	-0.36	-0.17	0.26	-0.78	-1.41
	(ii) Diluted	-	-	-	-	-

NOTES:

- 1 The above mentioned financial results have been reviewed by the Audit Committee and approved by the board of directors at meeting held on 01-09-2023
- In accordance with the requirement of regulation 33 of the SEBI (listing obligation and disclosure requirement) regulation 2015 the statutory auditor have performed review of the above audited financials results for quarter and year ended 31 march,2023
- 2 The figures of quarter ended 31st march are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year
- 3 The Company operates in Single Business Segment therefore Segment reporting is not applicable to the Company
- 4 The statement has been prepared in accordance with companies (Indian Accounting Standards) Rules, 2015 (Ind AS) Prescribed u/s133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 5 The adoption in Ind AS 115 "Revenue from Contracts with Customers", with effect from April,2018 did not have any significant impact to the financial results of the Company.
- 6 Previous period figures are regrouped, rearranged, where ever necessary. The Company has only one Segment

Place: Hyderabad
Date: 01-09-2023



for Sangam Health Care Products Limited

A. Balagopal
A. Balagopal
Director
DIN: 01712903

SANGAM HEALTH CARE PRODUCTS LIMITED
CIN NO- L24230TG1993PLC016731
Statement of Financial Position as at March 31, 2023

(Amt in Lakhs)

	Particulars	Note No.	As at March 31, 2023	As at March 31, 2022
I	ASSETS			
1	Non-current assets			
	(a) Property, plant and equipment	3	261.33	380.51
	(b) Right to use assets		-	-
	(c) Capital work in progress		-	-
	(d) Investment properties		-	-
	(e) Good will		-	-
	(f) Other intangible Assets		-	-
	(g) Intangible Assets under Development		-	-
	(h) Biological Assets other than Bearer Plants		-	-
	(d) Financial assets		-	-
	(i) Investments		-	-
	(ii) Trade receivables		-	-
	(iii) Loans		-	-
	(iv) other Financial assets		-	-
	(e) Deferred Tax Asset (Net)		-	-
	(f) Other non-current asset	4	33.59	33.59
	Total non-current assets (A)		294.93	414.10
2	Current assets			
	(a) Inventories	5	219.90	194.24
	(a) Financial assets			
	(i) Investments		-	-
	(ii) Trade receivables	6	62.75	61.10
	(iii) Cash and cash equivalents	7	15.62	1.21
	(iv) Bank Balances other than (iii) above		-	-
	(v) other financial assets		-	-
	(b) Current Tax Asset (Net)	8	-	-
	(c) Other current assets		214.29	238.92
	Total current assets (B)		512.57	495.47
	Non Current Assets Classified as Held for Sale (C)		-	-
	Total assets (A+B+C)		807.50	909.58
II	EQUITY AND LIABILITIES			
1	Equity			
	(a) Equity share capital	9	1,486.07	1,486.07
	(b) Other equity	10	(3,578.92)	(3,462.55)
	Total equity (A)		(2,092.85)	(1,976.48)
2	Liabilities			
(i)	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	11	2,086.46	29.78
	(ii) Trade Payables		-	-
	(iii) Other Financial Liabilities		-	-
	(b) Long term provisions		-	-
	(c) Deferred tax Liabilities(Net)	8	2.01	22.11
	(d) Other non Current Liabilities		-	-
	Total non-current liabilities (B)		2,088.47	51.88
(ii)	Current liabilities			
	(a) Financial liabilities			
	(i) Borrowings	12	21.45	2,310.19
	(ii) Trade payables	13	520.65	279.24
	(iii) Other financial liabilities		-	-
	(b) Short term provisions		-	-
	(c) Other current liabilities	14	269.77	244.73
	(d) Current Tax Liabilities (net)		-	-
	Total current liabilities (C)		811.87	2,834.17
	Total liabilities (D+B+C)		2,900.34	2,886.05
	Total equity and liabilities (A+D)		807.50	909.58

The notes are an integral part of the financial statements

1-2

As per our Report of even date

For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy*
Partner
Membership No: 213077
UDIN: 23213077BQTRQG1221

Place: Hyderabad
Date: 01.09.2023







For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

A. Balagopal
A. Balagopal
Managing Director
DIN:01712903

Padma Ghanakota
Padma Ghanakota
Director
DIN:07078176



SANGAM HEALTH CARE PRODUCTS LIMITED CIN:L24230TG1993PLC016731 Cash Flow Statement for the year ended 31st March, 2023		
Particulars	(Amt in Lakhs)	
	31.03.2023 (₹)	31.03.2022 (₹)
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	(136.48)	(172.61)
Adjustment for:		
Income tax expense recognised in profit or loss	-	-
Finance costs recognised in profit or loss	3.01	7.42
Investment income recognised in profit or loss	-	(1.78)
Gain on disposal of property, plant and equipment	-	-
Reversal of impairment loss on trade receivables	-	-
Depreciation and amortisation of non-current assets	121.72	121.72
Impairment of non-current assets	-	-
Net foreign exchange (gain)/loss	-	-
Expense recognised in respect of equity-settled share-based payments	-	-
Expense recognised in respect of shares issued in exchange for goods/services	-	-
Amortisation of financial guarantee contracts	-	-
Operating Profit before Working Capital Changes	(11.76)	(45.24)
Movement for Working Capital:		
(Increase)/decrease trade receivables	(1.65)	(18.74)
(Increase)/decrease in inventories	(25.66)	265.47
(Increase)/decrease in other assets	24.62	(11.19)
(Increase)/decrease in Deferred Tax	-	-
Increase/(decrease) in other payables	291.41	(150.92)
Increase/(decrease) in provisions	-	-
(Decrease)/increase in deferred revenue	-	-
(Decrease)/increase in other liabilities	25.04	60.88
Cash generated from operations	252.00	100.26
- Income taxes paid	-	-
Net Cash flow before extraordinary items	252.00	100.26
- Extraordinary & Prior period items	-	-
NET CASH FROM OPERATING ACTIVITIES	252.00	100.26
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Particulars	31.03.2023	31.03.2022
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Payments to acquire financial assets	-	-
Proceeds on sale of financial assets	-	-
Interest received	-	1.78
Royalties and other investment income received	-	-
Dividends received from associates	-	-
Net cash inflow on disposal of subsidiary	-	-
Net cash inflow on disposal of associate	-	-
NET CASH FROM INVESTING ACTIVITIES	-	1.78
C. CASH FLOW FROM FINANCING ACTIVITIES		
Particulars	31.03.2023	31.03.2022
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity instruments of the Company	-	-
Payment for debt issue costs Proceeds from borrowings	-	-
Repayment of borrowings	(232.05)	62.52
Proceeds from government loans	-	-
Interest paid	(1.01)	(7.42)
Long Term Provisions	-	(67.98)
NET CASH FROM FINANCING ACTIVITIES	(235.06)	(12.89)
NET INCREASE IN CASH & CASH EQUIVALENTS	16.93	88.14
Cash and cash equivalents at the beginning of the year	1.21	0.75
Effects of exchange rate changes on the balance of cash held in foreign currencies	-	-
Cash and cash equivalents at the end of the year	18.14	88.89
Reconciliation of cash and cash equivalents as per the cash flow Statement		
Cash and cash equivalents (Note no.7.3)	15.62	1.21
Balance as per statement of cash flows	15.62	1.21
As per our Report of even date For M M REDDY & CO., Chartered Accountants Firm Reg No:010371S		For and on behalf of the Board of Directors SANGAM HEALTH CARE PRODUCTS LIMITED  A. Bulugopal Managing Director DIN:01712903
CA. M. Madhusudhana Reddy Partner Membership No: 213077 UDIN: 23213077BQTRQG1221 Place: Hyderabad Date : 01.09.2023		 Padma Ghamakota Director DIN:07078176 



INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF Sangam Health Care Products Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of **Sangam Health Care Products Limited** (hereinafter referred to as the "Company") for the year ended 31 March 2023 ('standalone annual financial results'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31st March 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed



under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the



reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.

- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters


The standalone annual financial results include the results for the quarter ended 31st March 2023 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our opinion on the standalone annual financial results is not modified in respect of this matter.

For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg No.010371S



Date: 01-09-2023
Place: Hyderabad


M. Madhusudhana Reddy
Partner
Membership No.213077
UDIN: 23213077BGTRQG1221